Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
Apr 26, 2013, 01:14 ET
CAMBRIDGE, Mass., April 26, 2013 /PRNewswire/ -- Epizyme, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined.
Citigroup, Cowen and Company, LLC and Leerink Swann LLC will act as joint book-running managers for the offering. JMP Securities LLC and Wedbush Securities Inc. will act as co-managers for the offering.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (tel: 800-831-9146); Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York 11717, Attention: Prospectus Department, or by calling (631) 274-2806, or by faxing (631) 254-7140; or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Mass., 02110, or by email at [email protected] or by phone at 1-800-808-7525.
About Epizyme, Inc.
Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing).
For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.
Jason P. Rhodes
Chief Financial Officer
Email: [email protected]
Ph: 202.955.6222 ext. 2586
Email: [email protected]
SOURCE Epizyme, Inc.
Share this article